Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments.

Large studies on cognitive profiles of patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD-MCI) compared to Parkinson's disease (PD-MCI) are rare. Data from two multicenter cohort studies in AD and PD were merged using a unified base rate approach for the MCI diagnosis. Cognitive profiles were compared using scores derived from the Consortium to Establish a Registry for Alzheimer's Disease battery. Patients with AD-MCI showed lower standardized scores on all memory test scores and a language test. Patients with PD-MCI showed lower standardized scores in a set-shifting measure as an executive task. A cross-validated logistic regression with test scores as predictors was able to classify 72% of patients correctly to AD-MCI versus PD-MCI. The applied test battery successfully discriminated between AD-MCI and PD-MCI. Neuropsychological test batteries in clinical practice should always include a broad spectrum of cognitive domains to capture any cognitive changes.

Informations de copyright

© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Déclaration de conflit d'intérêts

AO, SW, SR, AP, ASp have nothing to disclose. LF received consulting honoraria or lecture fees from Abbott, Allergan, Avanir, Axon Neuroscience, Biogen, Boehringer Ingelheim, Eisai, Functional Neuromodulation, InfectoPharm, MerckSharpe & Dohme, NovoNordisk, Roche, and Willmar Schwabe outside the submitted work; received honoraria for work in study committees (endpoint committees or data/safety monitoring boards) from Avanir, Pharmatrophix, Forschungszentrum Jülich, Neuroscios, and Vivoryon, outside the submitted work. MH, FJ, JKo, WM have nothing to disclose. OP received consulting honoraria or lecture fees from Abbvie, Biogen, and Roche, outside the submitted work; received grant support/case payment for work in clinical trials from Biogen, Roche, Novartis, Janssen, Pharmatrophix, Eisai, and Fujifilm, outside the submitted work. AR, JWi have nothing to disclose. ILS reports grants from International Parkinson Fonds (Deutschland) GmbH (IPD), grants from Johnson & Johnson, a grant from the Michael J. Fox Foundation, grants from European Commission, H2020‐TWINN‐2015, outside the submitted work. SB, DB, JBS, KR, JWoj have nothing to disclose. JKa has received fees as speaker and/or advisor from UCB Pharma, Desitin, Novartis, Bial, Zambon, Medtronic, Desitin, AbbVie, NeuroDerm, and Teva Pharmaceuticals. ASt, MBG, RHR have nothing to disclose. KW reports personal fees from BIAL, personal fees from Desitin, personal fees from UCB, personal fees from Stadapharm, outside the submitted work. BM, CT, HUW, OR have nothing to disclose. RD reports personal fees from AbbVie, personal fees and non‐financial support from Axon Neuroscience, non‐financial support from Akademie für medizinische Fortbildung, personal fees from Agentur Süß, personal fees and non‐financial support from Bayer, grants from Baxter, personal fees from Bial, personal fees and non‐financial support from Biogen, personal fees and non‐financial support from Bayer Vital, personal fees and non‐financial support from BB‐Biotech, grants and non‐financial support from Deutsche Gesellschaft für Neurologie, non‐financial support from Deutscher Hausärzteverband, personal fees from Deutsches Zentrum für neurodegenerative Erkrankungen, grants and non‐financial support from Deutsche Parkinson Vereinigung, non‐financial support from Deutsche Gesellschaft Parkinson, personal fees and non‐financial support from Desitin, non‐financial support from European Brain Council, grants from EU‐Horizon, grants, personal fees and non‐financial support from Eisai, personal fees from Elsevier, grants from Ernst und Margot Faber Stiftung, personal fees and non‐financial support from Gemeinsamer Bundesausschuss, personal fees and non‐financial support from GE Healthcare, grants from GE Healthcare General Electric, personal fees and non‐financial support from International Parkinson and Movement Disorder Society, personal fees and non‐financial support from Institut für hausärztliche Fortbildung im Deutschen Hausärzteverband, personal fees and non‐financial support from IAK+, personal fees and non‐financial support from Johanniter, personal fees from Kohlhammer, grants and personal fees from Lilly, grants from Michael J. Fox Foundation, grants, personal fees and non‐financial support from Novartis, personal fees from Ono Pharma, personal fees and non‐financial support from Pfitzer, personal fees and non‐financial support from Paul‐Martini‐Stiftung, non‐financial support from Programm Demenz Prävention, personal fees and non‐financial support from Roche, personal fees and non‐financial support from Schwabe, personal fees from Springer Verlag, grants from Stichting International Parkinson Fonds, personal fees from Thieme Verlag, personal fees and non‐financial support from UCB Pharma, personal fees from Hummingbird, grants from BMBF, outside the submitted work; In addition, Dr. Dodel has a patent Alpha‐Synuclein Epitopbereiche (Bindungsstellen) natürlich vorkommender humaner Alpha‐Synuclein Autoantikörper zur Diagnostik und Therapie von Morbus Alzheimer und anderen neurodegenerativen Erkrankungen issued, a patent Diagnosis of Alzheimer's Disease and other neurodementia diseases of AD‐type and AD‐therapeutic application issued, a patent Diagnosis, Prohylaxis and Therapy of Alzheimer's Disease and other neurodementing disorders issued, a patent ELISA‐Test zur Bestimmung von Amyloid Beta Auto‐Antikörpern in humanen Serum‐/Plasma‐/CSF‐Proben issued, a patent Herstellung von oligomeren (trimeren) beta‐Amyloid Molekülen mittels spezifischer Mutationen issued, a patent Künstliche Mini‐Amyloide zur Diagnose und Behandlung der Alzheimer Demenz issued, a patent Naturally occurring autoantibodies against alpha‐synuclein that inhibit the aggregation and cytotoxicity of alpha‐synuclein mit Dr. Rentschler Holding GmbH & Co KG issued, and a patent Verfahren, insbesondere Enzyme‐linked Immunosorbent Assay (ELISA) zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit issued. MW has nothing to disclose. EK reports grants from the German Ministry of Education and Research, Parkinson Fonds Deutschland gGmbH, the German Parkinson Society; speaker honoraria from: Oticon GmbH, illy Pharma GmbH, Bernafon AG; Desitin GmbH, outside the submitted work.